Abstract: 3-Nitro-1H-1,2,4-triazole-based amides with a linear, rigid core and 3-nitrotriazolebased fluconazole analogs were synthesized as dual functioning antitrypanosomal agents. Such compounds are excellent substrates for type I nitroreductase (NTR) located in the mitochondrion of trypanosomatids and, at the same time, act as inhibitors of the sterol 14-demethylase (T.
 INTRODUCTION
About one sixth of the world's population, most living in developing countries, suffer from a series of infections collective known as neglected tropical diseases (NTDs). 1 In addition to killing more than 500,000 people each year, these illnesses impair physical and cognitive development of children, make it difficult to farm or earn a living, and limit productivity in the workplace. Two NTDs are American trypanosomiasis (also known as Chagas disease), which is causes by the protozoan parasite Trypanosoma cruzi and is endemic in 21 countries across Latin America, and human African trypanosomiasis (HAT) (also known as African sleeping sickness), which is prevalent across sub-Saharan Africa and caused by T. brucei rhodesiense and T. brucei gambiense Although the number of incidences of both infections has significantly declined in the past 20 years due to implementation of vector control initiatives, the diseases still remain a major global health issue, especially since the number of cases in non-endemic sites (United States, Australia, Europe and Japan) is rising, primarily due to international population migration and transfusion of contaminated blood.
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The therapeutic options for Chagas are currently limited to two drugs, both nitroheterocyclic compounds, nifurtimox (Nfx; Lampit®) and benznidazole (Bnz; Rochagan®), while the success of treatment depends on the phase of the disease. Thus, cure rates of 65-80% can be achieved in the acute phase, whereas only 15-30% cure rates have been reported among adults in the chronic stage. 5, 6 Besides the low efficacy in patients with chronic disease, safety and tolerability issues are also major drawbacks for these drugs. Therefore, the development of new, safer and more effective therapeutic treatments remains a key challenge for Chagas disease control.
Currently, inhibitors of the fungal sterol 14-demethylase enzyme (CYP51) represent a new form of treatment against Chagas disease and demonstrated promising efficacy in preclinical 4 studies. 7, 8 Additional pathogen-specific drug discovery efforts have resulted in inhibitors for the orthologous enzyme T. cruzi CYP51 (TcCYP51). [9] [10] [11] [12] One such compound, VNI, showed parasitological cures in both the acute and chronic in vivo Chagas model. 11 However, the antifungal agent posaconazole revealed 80% treatment failure in clinical trials in human patients with chronic Chagas disease while Bnz was proven more efficacious. 13 In addition, in newly designed in vitro assays, nitroheterocyclic compounds were more efficacious trypanocidal agents than four different CYP51 inhibitors, including antifungal drugs posaconazole and ravuconazole and two pyridine-based compounds, 14 suggesting that inhibitors of sterol biosynthesis may not be as efficient as single chemotherapeutic agents against Chagas disease as they are against fungal infections. Interestingly, a recent study with Bnz and posaconazole administered concomitantly or in sequence suggested a positive interaction between the two drugs, at least in an acute murine infection model. 15 We have recently demonstrated that another class of nitroheterocyclic compounds, 3-nitro-1H-1,2,4-triazoles, are very potent antichagasic agents both in vitro and in vivo, whereas several analogs showed very good in vitro efficacy against T. brucei rhodesiense as well. [16] [17] [18] [19] These studies clearly demonstrated that 3-nitrotriazole-based compounds are significantly more potent and less toxic than their 2-nitroimidazole-based counterparts, 19, 20 with part of the trypanocidal activity being dependent on the parasite's expression of an oxygen-insensitive type I nitroreductase (NTR), an enzyme absent from most other eukaryotes. 16, 17, 19 This same enzyme, via a series of 2 electron reduction reactions which lead to the production of toxic metabolites, is responsible for the trypanocidal activity of Nfx, Bnz and other nitroheterocyclic prodrugs in general. [21] [22] [23] [24] In this work we examined the possibility of synthesizing dual-functioning 3-nitrotriazolebased compounds; such compounds could potentially act as prodrugs via their reducible nitrogroup and, at the same time, be inhibitors of CYP51 enzyme via their triazole-based scaffold. 25 The synthesis of bifunctional agents has the advantage of combining the beneficial effects of nitroheterocyclics with the beneficial effects of ergosterol biosynthesis inhibitors in one molecule. To accomplish this task, we synthesized and evaluated in vitro and in vivo linear, rigid 3-nitrotriazole-based amides and 3-nitrotriazole-based carbinols (analogs of fluconazole), as potential antitrypanosomal/antichagasic agents, NTR substrates and TcCYP51 inhibitors.
 RESULTS AND DISCUSSION

Chemistry
The structures of synthesized compounds are shown in Table 1 . Their synthesis is straightforward and based on well-established chemistry outlined in Scheme 1. Thus, amides 2-9
were obtained by nucleophilic substitution of chloroacetamides 1a-g with the potassium salt of 3-nitrotriazole or 2-nitroimidazole under refluxing conditions. Similarly, nitro(triazole/ imidazole)-ketones 10-13 were synthesized by nucleophilic substitution of -bromoketones.
Carbinols 14-19 were obtained in one step by using a modified Corey-Chaykovsky reaction; 26 in this one-pot reaction, trimethylsulfoxonium iodide was used in a 2-propanol : aqueous KOH
(1:1) solution and the appropriate ketone was added to form in situ an oxirane; then 3-nitrotriazole was added followed by 1-h refluxing. Although the yields by using this method were low, the method is attractive due to its simplicity and short reaction time. The obtained carbinols 14-19 were used as racemic mixtures. When 2-nitroimidazole was used in the modified Corey-Chaykovsky reaction, the bicyclic compound 20 was formed as the final product, 6 presumably via an intramolecular aromatic nucleophilic substitution of the nitro-group by the hydroxyl-group. The sulfonamide 21 was formed by nucleophilic attack of the sodium salt of 3-nitrotriazole with the appropriate aziridine-sulfonamide (Scheme 1).
Biological Evaluation.
Anti-parasitic activity. Analysis of antichagasic activity. Linear, rigid amides 2-9: Although a detailed SARs evaluation cannot be conducted due to the limited number of compounds studied, we made the following observations: A chloro-substituent in the para position of a diphenyl-core in the rigid amide 5 increased the efficacy against T. cruzi by a factor of 3 compared to the cyano-substituted analog 2. Although 5 was slightly more toxic to L6 cells than compound 2, its SI for T. cruzi was also increased about 2-fold compared to 2 due to its better anti-chagasic efficacy; this cannot be attributed to lipophilicity since both compounds share similar clogP values, but perhaps to its lower PSA value (Table 1) . Chloro-substitution in the phenylthiazole-core of 3 was also beneficial for its antichagasic activity and selectivity compared to the difluoro-substitution in the analog 6. However, in this case, increased antichagasic efficacy may be related to the increased lipophilicity of 3 compared to 6. Reversing the order between the thiazole and phenyl rings in amide 8 slightly decreased antichagasic activity compared to 6 and once again, this reduction may be related to slightly lower lipohilicity compared to 6. Furthermore, this reversal lead to a slightly more toxic compound (compare 8 to 3 and 6). Replacing the terminal phenyl ring in the biphenyl core of 2 or 5 with a piperidinic group in 9, resulted in reduced efficacy against T.
cruzi, which seems to be attributed to a decreased clogP value ( Interestingly, carbinol 16, the analog of 17 without the 3-nitro group in the triazole ring, was still active against T. cruzi, most likely because of its relatively high lipophilicity. However, the lack of the nitro-group resulted in a 7-fold reduction in antichagasic potency compared to 17.
Carbinol 18 is the mono-nitrotriazole analog of fluconazole. This compound was 36-fold less potent than its more lipophilic analog 19, which has an additional phenyl ring in the side chain.
However, compound 18 was 8.5-fold more potent than fluconazole, which is less lipophilic and lacks the nitro-group ( Some ketones, precursors of the carbinols in Table 1 , were also evaluated for antichagasic activity. Interestingly, the 3-nitrotriazole-based ketones 10 and 11, precursors of carbinols 18 and 19, respectively, were found to be selectively active against T. cruzi ( Table 1 ). The pattern of lipophilicity and the presence of the nitro-group in the triazole ring were consistent with our predictions for efficacy. Thus, the more lipophilic 11 was more potent than 10, whereas ketone 12, the analog of 11 without the nitro-group, was only moderately active against T. cruzi and did not fulfill the TDR selectivity criteria. Once again, the 2-nitroimidazole analog of 11, ketone 13, was only moderately active against T. cruzi parasites, but also the most toxic compound to the host cells. From this evaluation, it appears that 3-nitrotriazole-based ketones represent another class of antichagasic agents. Finally, compound 22, the precursor of carbinols 14 and 15, was inactive against T. cruzi (Table 1) .
Analysis of anti-HAT activity. Linear, rigid amides 2-9:
With regard to the anti-HAT activity of amides 2-9, biphenyl amides 2 and 5 (which were active and moderately active, respectively) were more potent against T. b. rhodesiense than phenylthiazole-amides 3, 6, 7 and
8.
In fact, none of the latter demonstrated an acceptable selective anti-HAT activity ( Table 1 ).
The phenyl-thiodiazoleamide 4 did not show any anti-HAT activity, in part due to solubility issues as mentioned earlier, whereas the piperidinophenylamide 9 was inactive, perhaps because 30 Binding of a hererocyclic compound to CYP51 can be quantified spectroscopically by measuring a dose-response type 2
shift that occurs upon coordination of a Lewis-base atom of the ligand to the heme iron of the enzyme. 9 The first 3-nitrotriazole-based compound we tested as a potential TcCYP51 ligand was chlorothiophene-2-sulfonamide 23, with a flexible core ( Table 1 ). The biological properties of 23 have been described before 17 and are included in Table 1 for reference. This compound displayed a week affinity toward TcCYP51, providing a high K d value of 65.2  5.3 (Table 3) . Therefore, we assumed that compounds with a more rigid core could better fit in the active site of the enzyme and thus act as stronger inhibitors. Indeed, compound 2 with a linear rigid core inhibited the enzyme with an initial I/E 2 ratio (molar ratio of inhibitor/enzyme which causes a 2-fold decrease in enzyme activity) of 4 in a 5 min reaction. However, this ratio was increased to 36 in the 1 h reaction, indicating that inhibition by 2 was reversible. The 3-nitro-triazole-fluconazole analog 18 binds to TcCYP51 and induces the same typical type 2 spectral response as fluconazole ( Fig. 1 ), indicating at least initial coordination of the triazole N4 to the P450 heme iron. 9 However, 18 was a weaker binder than fluconazole (K d 0.606 versus 0.230 μM) (Table 3) .
To the contrary, carbinol 19, an analog of fluconazole with an elongated rigid side chain, elicited the spectral response in TcCYP51 with an apparent K d 10-fold stronger than fluconazole. In the reconstituted CYP51 reaction, 19 produced I/E 2 ratios of <1 and 3, in 5 min and 1 h reactions, respectively (Table 3 and (Table 3 ). This might be related to the nitro-group of 18, making this compound bifunctional.
Crystallography studies could shed more light on the orientation of these bifunctional agents in the TcCYP51 active site.
In vivo antichagasic activity. Compounds 2, 5, 18 and 19 were evaluated for in vivo antichagasic activity by using an acute T. cruzi infected murine model as described before. 19 Bnz was used in parallel as a positive control. Infected mice (5 mice/group) were treated i.p. for up to 10 consecutive days with each compound, at 15 mg/kg/day, except for compound 5 which was administered at 13 mg/kg/day. The Parasite Index (PI), which is an indicator for parasite clearance, was calculated after 5 and 10 days of treatment. 19 The data from these studies are summarized in Fig. 3 . All tested compounds reduced the PI to < 4% after 10-day treatment with statistical significance compared to the 10-day untreated control. The linear rigid amides 2 and 5
were able to reduce parasites to undetectable levels even after 5 days of treatment. However, only compound 5 yielded a statistically significant different PI value compared to untreated control after 5 days of treatment (P<0.0001), whereas for Bnz and compound 2 (treated in the same experiment) the corresponding P value was 0.080 and 0.0819, respectively. Carbinols 18
and 19 provided a PI value of 24.9 and 42.04, respectively, after 5-day administration but 13 without statistical significance compared to the untreated control (P = 0.1680 and 0.2706, respectively). Bnz in this latter experiment provided a PI value of 13.38 after 5-day treatment, also not statistically different from the untreated control (P = 0.2706). None of the tested compounds was toxic to mice at the given doses and administration shedule.
In vitro ADME studies. To understand better the in vivo activity of compounds 2 and 19 and explain the discrepancy between in vitro and in vivo potency, we performed some in vitro ADME studies ( Obviously, additional pharmacokinetic parameters (such as volume distribution and protein binding) which can affect the in vivo behavior of these compounds cannot be excluded.
It is concluded from the above data that 3-nitrotriazole-based linear rigid amides and carbinols are potent antichagasic agents via their dual functioning properties as substrates for trypanosomal type I NTR and as inhibitors of CYP51. In addition, these compounds demonstrate excellent Caco 2 permeability and metabolic stability in the presence of human or murine microsomes. Carbinols were slower in clearing the parasites in vivo compared to the linear rigid amides, however, both type of compounds were able to clear T. cruzi after 10-day treatment.
This is apparent in the images shown in Fig. 4 . Future experiments in a chronic murine model are or silica gel GF (1500 microns) plates (Analtech). All compounds were purified by preparative TLC chromatography on silica gel or alumina plates and also checked by HPLC (≥ 95% purity).
Synthesis of chlorides 1a-g: Some of the chlorides 1a-g are known in the literature and others are unknown or known through libraries but without any reference. The synthesis and spectroscopic data of 1a-g are provided in the supporting material.
General Synthetic Procedure of amides 2-9:
The potassium salt of 3-nitro-1,2,4-triazole or 2-nitroimidazole (1 eq) was formed in CH 3 CN (6-10 mL), by refluxing with KOH (1.2 eq) for 30 min. To this suspension 1a-g (1.1 eq) was added and the reaction mixture was refluxed under a nitrogen atmosphere for 9 h. In certain cases, 1a-g was added in CH 3 CN solution. The reaction 15 mixture was checked by TLC for completion of the reaction and the solvent was evaporated. The residue was dissolved in ethyl acetate and the inorganic salts were filtered away. Upon preparative TLC (silica gel or alumina, depending on the mobility of the major band; ethyl acetate-petroleum ether), the desired product was obtained usually as a powder. Purity was checked also by HPLC and it was > 95%.
N-[4-(4-cyanophenyl)phenyl]-2-(3-nitro-1H-1,2,4-triazol-1-yl)acetamide (2):
White 
N-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]-2-(3-nitro-1H-1,2,4-triazol-1-yl)acetamide (3):
N-[5-(4-chlorophenyl)-1,3,4-thiadiazol-2-yl]-2-(3-nitro-1H-1,2,4-triazol-1-yl) acetamide (4):
White General Synthetic Procedure of ketones 10-13: As in the case of amides 2-9, the potassium salt of 3-nitro-1,2,4-triazole or 2-nitroimidazole or 1,2,4-triazole (1 eq) was formed in CH 3 CN (6-10 ml), by refluxing with KOH (1.2 eq) for 30 min and the appropriate -bromoketone (1 eq) was added to this suspension. The reaction mixture was refluxed under nitrogen atmosphere for 5-6 h. The procedure for separation of the desired ketones 10-13 was analogous to that used for amides 2-9. (12) 
N-(4'-chloro-[1,1'-biphenyl]-4-yl)-2-(3-nitro-1H-1,2,4-triazol-1-yl)acetamide (5):
N-(4-(3,4-difluorophenyl)thiazol-2-yl)-2-(3-nitro-1H-1,2,4-triazol-1-yl)acetamide (6):
N-(3-(2-methylthiazol-4-yl)phenyl)-2-(3-nitro-1H-1,2,4-triazol-1-yl)acetamide (8):
2-(3-nitro-1H-1,2,4-triazol-1-yl)-N-(4-(piperidin-1-yl)phenyl)acetamide (9):
1-(2,4-difluorophenyl)-2-(3-nitro-1H-1,2,4-triazol-1-yl)ethan-1-one (10):
1-(4-phenylphenyl)-2-(1H-1,2,4-triazol-1-yl)ethan-1-one
2-(2-nitro-1H-imidazol-1-yl)-1-(4-phenylphenyl)ethan-1-one (13):
General Synthetic Procedure of carbinols 14-19 and compound 20:
The Corey-Chaykovsky reaction was applied for this synthesis and a one-pot reaction was adapted from an international patent 26 because of its short time, albeit with low yields. Briefly, in a 2-necked 25 mL round bottom flask, KOH (2.4 eq) was dissolved in 3 mL distilled water and an equal volume of 2-propanol was added.
Trimethylsulfoxonium iodide (1.2 eq) was added and stirred for 15 min under a nitrogen atmosphere.
Then, the appropriate ketone (1 eq) was added and stirring was continued for 15 min. Finally 3-nitro-1,2,4-triazole or 2-nitroimidazole or 1,2,4-triazole (1.2 eq) was added and the reaction mixture was refluxed for 1 h. 2-Propanol was evaporated and the aqueous solution was neutralized with 1% HCl. This solution was then extracted with dichloromethane and the organic layer washed with NaHCO 3 solution.
The organic layer was dried over Na 2 SO 4 and chromatographed by preparative TLC (silica gel, ethyl acetate plus 1% MeOH). When 2-nitroimidazole was used in the reaction mixture, a nucleophilic aromatic substitution of the nitro-group by the hydroxyl took place and the bicyclic-compound 20 was obtained as the final product. (14) -1H-1,2,4-triazol-1-yl)-2-(4-phenylphenyl)-3-(1H-1,2,4-triazol-1-yl) 
2-[4-(1H-imidazol-1-yl)phenyl]-1-(3-nitro-1H-1,2,4-triazol-1-yl)propan-2-ol
2-[4-(1H-imidazol-1-yl)phenyl]-1-(1H-1,2,4-triazol-1-yl)propan-2-ol (15):
2-(4-phenylphenyl)-1-(1H-1,2,4-triazol-1-yl)propan-2-ol (16):
1-(3-nitro-1H-1,2,4-triazol-1-yl)-2-(4-phenylphenyl)propan-2-ol (17):
2-(2,4-difluorophenyl)-1-(3-nitro-1H-1,2,4-triazol-1-yl)-3-(1H-1,2,4-triazol-1-yl)-propan-2-
1-(3-nitro
4-Methyl-N-[1-(3-nitro-1H-1,2,4-triazol-1-yl)-3-phenylpropan-2-yl]benzene-1-sulfonamide (21):
3-Nitro-1,2,4-triazole (0.68 mmol) was dissolved in dry 1-propanol (5 mL) and then NaH (60%, 1.05 eq) was added. Then the commercially available (Aldrich) S-(+)-2-benzyl-1-(ptosylaziridine) (0.68 mmol) was added and the reaction mixture was refluxed for 6 h. The reaction mixture was chromatographed on silica gel plates with ethyl acetate-petroleum ether Enzymatic activity studies with Type I NTR. Recombinant TbNTR was prepared and assayed as previously described. 33, 34 The activity of purified his-tagged TbNTR was assessed spectrophotometrically at 340 nm using various nitrotriazole substrates (100 µM) and NADH (100 µM) and expressed as nmol NADH oxidized min -1 mg -1 of enzyme.
Testing T. cruzi CYP51 as a potential inhibition target. Selected compounds (2, 18 and 19)
were evaluated as CYP51 ligand/inhibitors using purified full-length T. cruzi CYP51 protein sample. 28 Binding affinities of the compounds were estimated using spectral titration. The experiments were performed on a dualbeam Shimadzu UV-240IPC spectrophotometer in the wavelength range 350−450 nm at 25 °C in 2 mL tandem cuvettes at 2 μM P450 and ligand concentrations ranging from 0.5 to 10 μM. The apparent dissociation constants were calculated by plotting the absorbance changes in the difference spectra (ΔA425−390) upon titration against 21 free ligand concentration and fitting the data to a rectangular hyperbola in Sigma Plot Statistics.
Inhibitory potencies of the compounds were compared in the reconstituted CYP51 reaction 5 min and 1 h, at 50/2/1 molar ratio substrate/inhibitor/enzyme. P450 concentration in the reaction mixture was 1 μM. The reaction products were analyzed on a reverse-phase HPLC system (Waters) equipped with a C18Nova Pak column and a β-RAM detector (INUS Systems, Inc.).
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In vivo antichagasic activity assessment of selected compounds. For in vivo studies, a
Brazilian strain trypomastigotes from transgenic T. cruzi parasites expressing firefly luciferase were used as described before. 19 Briefly, parasites were injected in Balb/c mice (10 5 trypomastigotes per mouse) and three days later mice were anesthesized by inhalation of isofluorane, followed by an injection with 150 mg/kg of D-luciferin potassium-salt in PBS. Mice were imaged 5 to 10 min after injection of luciferin with an IVIS 100 (Xenogen, Alameda, CA) and the data acquisition and analysis were performed with the software LivingImage (Xenogen) as described before. 35 Treatment with test compounds was started 4 days after infection at a specific concentration (usually 15 mg/kg/day x 10 days) by i.p. injection. The vehicle control was 2% methylcellulose + 0.5% Tween 80 and groups of 5 mice/group were used. In the vehicle control group 10 mice were used. Mice were imaged on days 5 and 10 as above. Parasite index was calculated as the ratio of parasite levels in treated mice compared to the control group and multiplied by 100. The ratio of parasite levels is calculated for each animal dividing the luciferase signal after treatment by the luciferase signal on the first imaging (before treatment).
Mean values of all animals in each group  SD were then used to calculate the parasite index.
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In vitro ADME studies. ADME in vitro studies were performed by APREDICA (Watertown, MA). Samples were analyzed by LC/MS/MS using an Agilent 6410 mass spectrometer coupled with an Agilent 1200 HPLC and a CTC PAL chilled autosampler, all controlled by MassHunter 22 software (Agilent). After separation on a C18 reverse phase HPLC column (Agilent, Waters, or equivalent) using an acetonitrile-water gradient system, peaks were analyzed by mass spectrometry (MS) using ESI ionization in MRM mode.
Microsomal stability screen: Each test compound was dissolved in DMSO and incubated (37 ºC) at 1 μM final concentration with 0.3 mg/mL of microsomal protein in 100 mM potassium phosphate, 3 mM MgCl 2 , pH 7.4, in the presence or absence of 2 mM NADPH (to detect NADPH-free degradation) for up to 60 min as has been described before. 19 Data were reported as % remaining parent compound. Vehicle (for comp. 5) 
Caco
